Cleveland BioLabs is a clinical stage biotechnology company establishing a pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The company’s lead compound is being developed as both a radiation countermeasure and a cancer treatment. CBLI has two operating subsidiaries, Incuron LLC, and Panacela Labs, Inc., as well as strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children’s Cancer Institute Australia and the Armed Forces Radiobiology Research Institute. For more information visit the company’s Web site at www.cbiolabs.com
Let us hear your thoughts below: